1. Home
  2. GKOS vs HLNE Comparison

GKOS vs HLNE Comparison

Compare GKOS & HLNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$116.08

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Logo Hamilton Lane Incorporated

HLNE

Hamilton Lane Incorporated

HOLD

Current Price

$134.33

Market Cap

5.4B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
HLNE
Founded
1998
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.4B
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
GKOS
HLNE
Price
$116.08
$134.33
Analyst Decision
Strong Buy
Buy
Analyst Count
13
9
Target Price
$125.54
$160.89
AVG Volume (30 Days)
865.8K
569.2K
Earning Date
10-29-2025
02-03-2026
Dividend Yield
N/A
1.61%
EPS Growth
N/A
19.80
EPS
N/A
5.55
Revenue
$469,820,000.00
$733,070,000.00
Revenue This Year
$31.15
$8.42
Revenue Next Year
$24.15
$19.65
P/E Ratio
N/A
$24.24
Revenue Growth
30.38
13.01
52 Week Low
$73.16
$111.98
52 Week High
$163.71
$179.19

Technical Indicators

Market Signals
Indicator
GKOS
HLNE
Relative Strength Index (RSI) 76.42 63.76
Support Level $105.88 $127.92
Resistance Level $116.72 $135.56
Average True Range (ATR) 3.26 3.80
MACD 0.07 0.88
Stochastic Oscillator 94.61 91.56

Price Performance

Historical Comparison
GKOS
HLNE

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About HLNE Hamilton Lane Incorporated

Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.

Share on Social Networks: